| Publisher’s Note: Join Fierce Biotech Editors and industry leaders at the Fierce Biotech Summit to network and gain exclusive insights. Don’t miss out — register now! |
Today’s Big NewsSep 10, 2024 |
|
Still Time to Shine! Submission deadline for the Fierce Life Sciences Innovation Awards have been extended to September 12. Click to submit your entry and learn more about what winner's will receive. 
|
|
| By Nick Paul Taylor AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate has failed to improve overall survival in non-small cell lung cancer, extending the list of molecules that have fallen short in head-to-head fights with docetaxel. |
|
|
|
By Kevin Dunleavy With a strong track record for identifying diamonds in the rough, Bain Capital Life Sciences (BCLS) has become a powerful force in biotech investing, revealing a fourth fund totaling $3 billion. |
By James Waldron The recent decision to merge Genentech’s two cancer departments was made for “scientific reasons,” according to executives. |
By Nick Paul Taylor Viridian Therapeutics’ phase 3 thyroid eye disease clinical trial has hit its primary and secondary endpoints. But with Amgen’s Tepezza already on the market, the data leave scope to question whether the biotech has done enough to differentiate its asset and unseat the incumbent. |
|
Partner with us for vaccine manufacturing that expertly integrates novel analytical and process-related technologies with your program's unique needs, ensuring efficient tech transfer and rapid scaling. Grow with us. 
|
|
By Gabrielle Masson On the heels of disappointing low-dose data results, Zealand Pharma is back with separate findings for its GLP-1/GLP-2 receptor dual agonist that have emboldened the biotech to push the candidate into phase 2b development. |
By Zoey Becker Gilead is paying $35 million to access Genesis' tech. The deal covers three targets, with an option for more down the line. |
By James Waldron Matt Gline is back with a new ‘vant’ company, after the Roivant Sciences CEO paid Bayer $14 million upfront for the rights to a phase 2-ready hypertension drug. |
By Fraiser Kansteiner Late Monday, the U.S. House of Representatives voted 306-81 in favor of the BIOSECURE Act, which was introduced in January and seeks to halt federal contracts with five named Chinese life-sci companies: WuXi AppTec, WuXi Biologics, BGI Group, MGI and Complete Genomics. |
By Darren Incorvaia Gentronix, a British contract research organization that specializes in genetic toxicology, is officially off the market. Danish CRO Scantox, with its majority owner Impilo, bought Gentronix and integrated the company into its toxicology operations. |
By Conor Hale Au revoir, Abiomed. Goodbye, DePuy. Bon voyage, Biosense. So long, Cerenovus. Adios, Ethicon. |
By Heather Landi Amy Abernethy left Verily earlier this year as its chief medical officer and has now teamed up with a long-time colleague to launch an initiative that takes a new approach to modernizing clinical research. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "The Top Line," we’re looking at what goes into manufacturing and supply of flu vaccines. |
|
|---|
|
|
Whitepaper Facing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
Whitepaper We interviewed dozens of biopharma leaders on the critical success factors for building a Best Practice commercial organization. This report shares what we learned. Sponsored by: Blue Matter Consulting |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
